0001437402false00014374022024-08-012024-08-01


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 1, 2024
Image_0.jpg
ARDELYX, INC.
(Exact name of registrant as specified in its charter)
Delaware001-3648526-1303944
(State or other jurisdiction
of incorporation)		(Commission
File Number)		(IRS Employer
Identification Number)
400 FIFTH AVE., SUITE 210, WALTHAM, MASSACHUSETTS 02451
(Address of principal executive offices, including Zip Code)
Registrant’s telephone number, including area code: (510) 745-1700
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.0001ARDXThe Nasdaq Global Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company  ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  o



Item 2.02    Results of Operations and Financial Condition.

On August 1, 2024, Ardelyx, Inc. (the “Company”) announced its financial results for the quarter ended June 30, 2024. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information furnished under this Item 2.02 shall not be considered “filed” under the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any future filing under the Securities Act of 1933, as amended, or under the Securities Exchange Act of 1934, as amended, unless the Company expressly sets forth in such future filing that such information is to be considered “filed” or incorporated by reference therein.
Item 9.01    Financial Statements and Exhibits.
(d) Exhibits.
Exhibit
No.		Description
99.1
104Cover Page Interactive Data File (embedded within the Inline XBRL document).


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: August 1, 2024ARDELYX, INC.
By:/s/ Justin Renz
Justin Renz
Chief Financial and Operations Officer

image_0.jpg
Exhibit 99.1

Ardelyx Reports Second Quarter 2024 Financial Results and Provides Business Update

IBSRELA generates $35.4 million in net product sales revenue

XPHOZAH generates $37.1 million in net product sales revenue

Company ends Q2 with approximately $186 million in cash and investments

Conference call scheduled for 4:30 PM Eastern Time


WALTHAM, Mass., August 1, 2024 - Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today reported financial results for the second quarter ended June 30, 2024 and provided a business update.

“In the second quarter, Ardelyx demonstrated our commitment to our mission and to ensuring that patients remain at the forefront of all of our efforts. We continued to drive expanded awareness and use of our two first-in-class medicines that represent new therapeutic options for patients who continue to have significant unmet medical needs. In addition, importantly, we are standing with the entire kidney community and fighting for patients whose health is at risk,” said Mike Raab, president and chief executive officer of Ardelyx.

Raab continued, “IBSRELA’s strong performance continued with consistent quarter-over-quarter gains. This performance further strengthens our conviction that IBSRELA is on track to achieve at least ten percent market share and $1 billion in annual sales before patent expiry. IBSRELA is providing meaningful clinical benefits to patients at a time when the need among IBS-C patients to address their symptoms remains significant. We believe IBSRELA is well placed to address this unmet need and we continue to invest, including the ongoing expansion of our sales team to further our growth trajectory. XPHOZAH’s remarkable performance continued, a clear indicator of the need for a novel therapy, like XPHOZAH, to help patients achieve target phosphorus levels. This is why it is so important that we take steps to protect patients against the dire consequences of the access restrictions that will occur if CMS moves oral-only phosphate lowering therapies into the End-Stage Renal Disease Prospective Payment System.”

IBSRELA® (tenapanor) records $35.4 million in net product sales revenue in Q2 2024
U.S. net product sales revenue for IBSRELA during the second quarter of 2024 was $35.4 million, showing approximately 25% quarter-over-quarter growth compared to the first quarter of 2024, and significant growth compared to the second quarter of 2023. The strong performance reflects the meaningful demand for IBSRELA, demonstrated by continued increases in new and refill prescriptions as well as growth in new and repeat writing healthcare providers.

Ardelyx continues to expect full-year 2024 U.S. net product sales revenue for IBSRELA to be between $140.0 and $150.0 million.

XPHOZAH® (tenapanor) launch progresses, records $37.1 million net product sales revenue during Q2 2024
Ardelyx continued to see a strong response to XPHOZAH from the nephrology community. U.S. net product sales revenue during Q2 2024 was $37.1 million, demonstrating significant quarter-over-quarter growth compared to the $15.2 million in net product sales revenue reported during the first quarter of 2024.

During the quarter, the company announced that an analysis of the Centers for Medicaid and Medicare Services (CMS) End-Stage Renal Disease Prospective Payment System (ESRD PPS) proposed rule to include oral-only medicines in the ESRD PPS revealed that the policy and the manner in which CMS intends to implement it are likely to cause significant restrictions on the use of XPHOZAH for all patients, irrespective of insurance coverage, because it interferes with the essential and appropriate shared decision-making between healthcare professionals and their patients. As part of an effort to protect patient access to XPHOZAH, the company announced on July 2 that it has chosen not to apply for the ESRD PPS Transitional Drug Add-on Payment Adjustment; and on July 18, the company announced that it has filed a lawsuit against CMS in partnership with the American Association of Kidney Patients and the National Minority Quality Forum claiming that CMS has violated its statutory and regulatory authority in its determination to include oral-only phosphate lowering therapies in the ESRD PPS.



Other Corporate Developments
•In June, the company presented data detailing educational needs related to irritable bowel syndrome with constipation (IBS-C) across healthcare disciplines in a poster at the 2024 American Association of Nurse Practitioners National Conference.
•The company had a significant presence at the 2024 Digestive Disease Week Conference, held May 18-21, 2024. The company presented two posters providing additional data supporting IBSRELA. The company also sponsored a Product Theater titled: “Discover IBSRELA: a Different Mechanism of Action to Treat Adults With IBS-C: A Case-Based Discussion,” where Brooks Cash, MD, led an engaging discussion about important clinical considerations for managing IBS-C in adult patients.
•The company had a significant presence at the National Kidney Foundation 2024 Spring Clinical Meetings, held May 14-18, 2024. The company presented three posters providing additional data supporting XPHOZAH. The company also sponsored an Exhibitor Spotlight titled “A New Paradigm: Rethinking Hyperphosphatemia Management,” where David M. Spiegel, MD and Lisa Gutekunst MSEd, RD, CSR, CDN, FNKF, discussed the clinical application of XPHOZAH as add-on therapy for the many dialysis patients on a phosphate binder with serum phosphorus levels above guideline-established targets.

Second Quarter 2024 Financial Results
•    Cash Position: As of June 30, 2024, the company had total cash, cash equivalents and short-term investments of $186.0 million, as compared to total cash, cash equivalents and short-term investments of $184.3 million as of December 31, 2023.

•    Revenues: Total revenue for the quarter ended June 30, 2024 was $73.2 million, compared to $22.3 million in total revenue during the quarter ended June 30, 2023, primarily reflecting increased net product sales.
–IBSRELA U.S. net product sales revenue was $35.4 million, compared to $18.3 million during the same period of 2023.
–XPHOZAH U.S. net product sales revenue was $37.1 million, with no comparable revenue during the same period of 2023.
–There was no material product supply revenue during the quarter ended June 30, 2024, compared to $3.3 million during the same period of 2023.
–Licensing revenue was $19 thousand, compared to $764 thousand during the same period of 2023.
–Non-cash royalty revenue related to the sale of future royalties was $0.6 million, with no comparable revenue during the same period of 2023.

•    R&D Expenses: Research and development expenses were $12.8 million for the quarter ended June 30, 2024, compared to $8.3 million for the quarter ended June 30, 2023.

•    SG&A Expenses: Selling, general and administrative expenses were $64.7 million for the quarter ended June 30, 2024, an increase of $37.5 million compared to $27.2 million for the quarter ended June 30, 2023. The increase in selling, general and administrative expenses was primarily due to increased costs associated with the ongoing commercialization of IBSRELA and XPHOZAH.

•    Net Loss: Net loss for the quarter ended June 30, 2024 was $16.5 million, or $(0.07) per share, compared to net loss of $17.1 million, or $(0.08) per share, for the quarter ended June 30, 2023. The $16.5 million net loss for the second quarter of 2024 included share-based compensation expense of $10.8 million and non-cash interest expense related to the sale of future royalties of $1.6 million.

Conference Call Details
The company will host a conference call today, August 1, 2024, at 4:30 PM ET to discuss today’s announcement. To participate in the conference call, please dial (844) 481-2838 (domestic) or (412) 317-1858 (international) and ask to be joined into the Ardelyx call. A webcast of the call can also be accessed by visiting the Investor page of the company's website, www.ardelyx.com, and will be available on the website for 30 days following the call.



IMPORTANT SAFETY INFORMATION (IBSRELA)

WARNING: RISK OF SERIOUS DEHYDRATION IN PEDIATRIC PATIENTS
IBSRELA is contraindicated in patients less than 6 years of age; in nonclinical studies in young juvenile rats administration of tenapanor caused deaths presumed to be due to dehydration. Avoid use of IBSRELA in patients 6 years to less than 12 years of age. The safety and effectiveness of IBSRELA have not been established in patients less than 18 years of age.

CONTRAINDICATIONS
•IBSRELA is contraindicated in patients less than 6 years of age due to the risk of serious dehydration.
•IBSRELA is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction.

WARNINGS AND PRECAUTIONS
Risk of Serious Dehydration in Pediatric Patients
•IBSRELA is contraindicated in patients below 6 years of age. The safety and effectiveness of IBSRELA in patients less than 18 years of age have not been established. In young juvenile rats (less than 1 week old; approximate human age equivalent of less than 2 years of age), decreased body weight and deaths occurred, presumed to be due to dehydration, following oral administration of tenapanor. There are no data available in older juvenile rats (human age equivalent 2 years to less than 12 years).
•Avoid the use of IBSRELA in patients 6 years to less than 12 years of age. Although there are no data in older juvenile rats, given the deaths in younger rats and the lack of clinical safety and efficacy data in pediatric patients, avoid the use of IBSRELA in patients 6 years to less than 12 years of age.

Diarrhea
Diarrhea was the most common adverse reaction in two randomized, double-blind, placebo-controlled trials of IBS-C. Severe diarrhea was reported in 2.5% of IBSRELA-treated patients. If severe diarrhea occurs, suspend dosing and rehydrate patient.

MOST COMMON ADVERSE REACTIONS
The most common adverse reactions in IBSRELA-treated patients (incidence ≥2% and greater than placebo) were: diarrhea (16% vs 4% placebo), abdominal distension (3% vs <1%), flatulence (3% vs 1%) and dizziness (2% vs <1%).

INDICATION
IBSRELA (tenapanor) is indicated for the treatment of Irritable Bowel Syndrome with Constipation (IBS-C) in adults.

Please see full Prescribing Information, including Boxed Warning, for additional risk information.

IMPORTANT SAFETY INFORMATION (XPHOZAH)

CONTRAINDICATIONS
XPHOZAH is contraindicated in:
•Pediatric patients under 6 years of age
•Patients with known or suspected mechanical gastrointestinal obstruction

WARNINGS AND PRECAUTIONS
Diarrhea
Patients may experience severe diarrhea. Treatment with XPHOZAH should be discontinued in patients who develop severe diarrhea.



MOST COMMON ADVERSE REACTIONS
Diarrhea, which occurred in 43-53% of patients, was the only adverse reaction reported in at least 5% of XPHOZAH-treated patients with CKD on dialysis across trials. The majority of diarrhea events in the XPHOZAH-treated patients were reported to be mild-to-moderate in severity and resolved over time, or with dose reduction. Diarrhea was typically reported soon after initiation but could occur at any time during treatment with XPHOZAH. Severe diarrhea was reported in 5% of XPHOZAH-treated patients in these trials.

INDICATION
XPHOZAH (tenapanor), 30 mg BID, is indicated to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.

For additional safety information, please see full Prescribing Information.

About Ardelyx
Ardelyx was founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA® (tenapanor) and XPHOZAH® (tenapanor). Ardelyx has agreements for the development and commercialization of tenapanor outside of the U.S. Kyowa Kirin commercializes PHOZEVEL® (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been submitted in China with Fosun Pharma. Knight Therapeutics commercializes IBSRELA in Canada. For more information, please visit https://ardelyx.com/ and connect with us on X (formerly known as Twitter), LinkedIn and Facebook.

Forward Looking Statements
To the extent that statements contained in this press release are not descriptions of historical facts regarding Ardelyx, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor of the Private Securities Reform Act of 1995, including Ardelyx’s current expectation regarding opportunities for continued IBSRELA and XPHOZAH adoption; the potential market share for IBSRELA and annual U.S. net product sales revenue prior to patent expiry; projected U.S. net product sales revenue for IBSRELA for full year 2024; the impact of the Transitional Drug Add-on Payment Adjustment (TDAPA) period and the ESRD PPS policy on access to XPHOZAH; and Ardelyx’s current belief that not applying for TDAPA may help to protect patient access to XPHOZAH. Such forward-looking statements involve substantial risks and uncertainties that could cause Ardelyx's future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, uncertainties associated with the development of, regulatory process for, and commercialization of drugs in the U.S. and internationally. Ardelyx undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ardelyx's business in general, please refer to Ardelyx's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 1, 2024, and its future current and periodic reports to be filed with the Securities and Exchange Commission.

Investor and Media Contacts:
Caitlin Lowie
clowie@ardelyx.com



image_0.jpg
Ardelyx, Inc.
Condensed Balance Sheets
(In thousands)
June 30, 2024December 31, 2023
(Unaudited)(1)
Assets
Cash and cash equivalents$41,890$21,470
Investments144,071162,829
Accounts receivable37,24122,031
Prepaid commercial manufacturing14,79718,925
Prepaid commercial manufacturing, non-current—4,235
Inventory, current13,75612,448
Inventory, non-current69,67637,039
Property and equipment, net1,0161,009
Right-of-use assets4,3245,589
Prepaid and other assets16,71712,004
Total assets$343,488$297,579
Liabilities and stockholders' equity
Accounts payable$10,881$11,138
Accrued compensation and benefits10,45812,597
Current portion of operating lease liability3,5504,435
Deferred revenue20,44215,826
Accrued expenses and other liabilities26,71815,041
Operating lease liability, net of current portion1,0961,725
Long-term debt100,24949,822
Deferred royalty obligation related to the sale of future royalties23,10420,179
Stockholders' equity146,990166,816
Total liabilities and stockholders' equity$343,488$297,579
(1) Derived from the audited financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023.

image_0.jpg
Ardelyx, Inc.
Condensed Statements of Operations
(Unaudited)
(In thousands, except share and per share amounts)
Three Months Ended June 30,Six Months Ended June 30,
2024202320242023
Revenues:
Product sales, net:
IBSRELA$35,445 $18,309 $63,806 $29,664 
XPHOZAH37,146 — 52,297 — 
Total product sales, net72,591 18,309 116,103 29,664 
Product supply revenue13 3,260 2,139 3,262 
Licensing revenue19 764 36 776 
Non-cash royalty revenue related to the sale of future royalties599 — 967 — 
Total revenues73,222 22,333 119,245 33,702 
Cost of goods sold:
Cost of product sales1,405 492 2,418 864 
Other cost of revenue8,031 2,997 14,146 4,162 
Total cost of goods sold9,436 3,489 16,564 5,026 
Operating expenses:
Research and development12,762 8,282 23,341 17,375 
Selling, general and administrative64,654 27,186 117,648 53,989 
Total operating expenses77,416 35,468 140,989 71,364 
Loss from operations(13,630)(16,624)(38,308)(42,688)
Interest expense(3,326)(1,075)(5,682)(2,103)
Non-cash interest expense related to the sale of future royalties(1,576)(968)(3,278)(1,937)
Other income, net2,145 1,546 4,484 2,848 
Loss before provision for income taxes(16,387)(17,121)(42,784)(43,880)
Provision for income taxes67 — 188 14 
Net loss$(16,454)$(17,121)$(42,972)$(43,894)
Net loss per share of common stock - basic and diluted$(0.07)$(0.08)$(0.18)$(0.21)
Shares used in computing net loss per share - basic and diluted234,571,192 214,951,127 233,818,576 211,009,029 

v3.24.2.u1
Cover
Aug. 01, 2024
Cover [Abstract]  
Document Type 8-K
Document Period End Date Aug. 01, 2024
Entity Registrant Name ARDELYX, INC.
Entity Incorporation, State or Country Code DE
Entity File Number 001-36485
Entity Tax Identification Number 26-1303944
Entity Address, Address Line One 400 FIFTH AVE.
Entity Address, Address Line Two SUITE 210
Entity Address, City or Town WALTHAM
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02451
City Area Code 510
Local Phone Number 745-1700
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.0001
Trading Symbol ARDX
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Entity Central Index Key 0001437402
Amendment Flag false
Ardelyx (NASDAQ:ARDX)
Historical Stock Chart
From Jul 2024 to Aug 2024 Click Here for more Ardelyx Charts.
Ardelyx (NASDAQ:ARDX)
Historical Stock Chart
From Aug 2023 to Aug 2024 Click Here for more Ardelyx Charts.